Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going?

Dermato-Endocrinology

Volumn 3, Issue 3, 2011, Pages 180-186

  Trémezaygues, Léa ^a   Reichrath, Jörg ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CYP27B1; Psoriasis; Skin; Vdr; Vitamin D

Indexed keywords

22 OXACALCITRIOL; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CYCLOSPORIN; DITHRANOL; ETRETIN; METHOTREXATE; STEROID; TACALCITOL; TAZAROTENE; VITAMIN D DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; BURNING SENSATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DERMATITIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; LYMPHOMA; NONHUMAN; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 80054035094     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.17534     Document Type: Review

References (91)

1. Holick MF. Vitamin D deficiency. NEJM 2007; 357:266-81.
2. 3 in an in vitro human skin equivalent model. J Invest Dermatol 2001; 117:1179-85.
3. 3 production by human keratinocytes. J Clinical Invest 1886; 78:557-66.
4. 3 or UVB radiation in keratinocytes of human skin equivalents-a preliminary study. Arch Dermatol Res 1999; 291:507-10.
5. 3: dependence on cell culture conditions. J Invest Dermatol 1996; 106:510-6.
6. Reichrath J, Holick MF. Psoriasis and other skin diseases. In: D Feldman, JW Pike, JS Adams. (editors) Vitamin D. Third Edition, Elsevier Academic Press, Amsterdam 2011; 1891-906.
7. Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36:19-28. (Pubitemid 27043869)
8. 3) application in the treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol 1997; 77:268-72.
9. Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, et al. Molecular biology of the vitamin D hormone. Recent Prog Horm Res 1988; 44:263-305.
10. 3 increases intracellular calcium in human keratinocytes. Br J Dermatol 1991; 124:12230-5.
11. 3 increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. J Nutr Biochem 1990; 1:81-7.
12. Haussler MR. Vitamin D receptors: nature and function. Annu Rev Nutr 1986; 6:527-62.
13. Baker AR, Mc Donnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85:3294-8.
14. 3 receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97:230-9.
15. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown under serum-free conditions. J Invest Dermatol 1986; 86:709-14.
16. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1-alpha,25-dihydroxyvitamin D3. Endocrinol 1983; 113:1950-7. (Pubitemid 14213553)
17. 3 and its analogs on dendritic cell function. J Cell Biochem 2003; 88:323-6.
18. Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjö A, Törmä H, Ståhle M. Vitamin D Induces the Antimicrobial Protein hCAP18 in Human Skin. J Invest Dermatol 2005; 124:1080-2. (Pubitemid 40629115)
19. Gombard HF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly upregulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19:1067-77. (Pubitemid 40946432)
20. 3 to "program" T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007; 8:285-93.
21. Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, Wheelwright M, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 2010; 107:22593-8.
22. Sakai Y, Demay MB. Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 2000; 141:2043-9. (Pubitemid 32274354)
23. 3 inhibits hedgehog signalling and proliferation in murine basal cell carcinomas. Cancer Prev Res 2011; 4:744-51.
24. 3 and its Analogues for the Treatment of Psoriasis. In: Holick MF (Editor). Vitamin D: Physiology, Molecular Biologic and Clinical Aspects. The Humana Press Inc., Totowa, New York 1999; 357-73.
25. 3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T-cells. J Allergy Clin Immunol 2011; 127:1532-40.
26. Solvoll K, Soyland E, Sandstad B, Drevon CA. Dietary habits among patients with atopic dermatitis. Eur J Clin Nutr 2000; 54:93-7. (Pubitemid 30162878)
27. Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol 2011; 164:1078-82.
28. 3 downregulates IgE-mediated murine biphasic cutaneous reactions. Int Arch Allergy Immunol 1996; 111:71-6.
29. 3. Arch Dermatol Res 2010; 302:401-8.
30. 3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor α. J Biol Chem 1997; 272:8997-9001.
31. 3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001; 117:1241-9.
32. Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol 1996; 106:637-41. (Pubitemid 26120578)
33. Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 2007; 299:487-91. (Pubitemid 350160056)
34. Okita H, Ohtsuka T, Yamakage A, Yamazaki S. Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Dermatol Res 2002; 294:159-62. (Pubitemid 34744001)
35. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol 1999; 112:113-6.
36. Saeki H, Asano N, Tsunemi Y, Takekoshi T, Kishimoto M, Mitsui H, et al. Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris. J Dermatol Sci 2002; 30:167-71. (Pubitemid 36159028)
37. Lee DY, Park BS, Choi KH, Jeon JH, Cho KH, Song KY, et al. Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. Arch Dermatol Res 2002; 294:1-5.
38. Kontula K, Välimäki S, Kainulainen K, Viitanen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. Br J Dermatol 1997; 136:147-8.
39. Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol 1998; 110:301-2. (Pubitemid 28144610)
40. Colin EM, Weel AEAM, Uitterlinden AG, Buurman CJ, Birkenhäger JC, Pols HAP, et al. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25-dihydroxyvitamin D3. Clin Endocrinol 2000; 52:211-6. (Pubitemid 30108268)
41. Staberg B, Oxholm A, Klemp P, Christiansen C. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereol 1987; 67:65-8.
42. Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcemia-induced pustular psoriasis of von Zumbusch. New experience with an old syndrome. Ann Intern Med 1984; 100:677-80. (Pubitemid 14143941)
43. Stone OJ. Chloroquine, ground substance, aggravation of psoriasis. Int J Dermatol 1985; 24:539.
44. MacLaughlin JA, Gange W, Taylor D, Smith E, Holick MF. Cultured psoriatic fibroblasts from involved and uninvolved sites have partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1985; 82:5409-12. (Pubitemid 15012114)
45. 3 Med J Osaka Univ 1985; 35:3-4.
46. 3 treatment in psoriasis vulgaris. Br J Dermatol 1986; 115:421-9.
47. 3 and parathyroid hormone related peptide in dermatology: a new perspective. J Invest Dermatol (Symp Proc) 1996; 1:1-9.
48. 3) for the treatment of psoriasis. Br J Dermatol 1996; 134:238-46.
49. 3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988; 119:223-30.
50. van de Kerkhof PCM, van Bokhoven M, Zultak M, Czarnetzki BM. A double-blind study of topical 1α-25- dihydroxyvitamin D3 in psoriasis. Br J Dermatol 1989; 120:661-4. (Pubitemid 19143299)
51. Barker JN, Ashton RE, Marks R, Harris RI, Berth- Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dosefinding study with active comparator. Br J Dermatol 1999; 141:274-8. (Pubitemid 29397995)
52. 3 for the treatment of plaque psoriasis: a pilot study. Br J Dermatol 2001; 144:500-6.
53. Miyachi Y, Ohkawara A, Ohkido M, Harada S, Tamaki K, Nakagawa H, et al. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol 2002; 12:463-8. (Pubitemid 35205136)
54. van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Honigsmann H, Marks R, et al. Longterm efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002; 146:414-22. (Pubitemid 34603813)
55. Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerhof PCM, Larko O, et al. Double-blind right/left comparison of calcipotriol and betametasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337:193-6.
56. Serup J. Calcipotriol irritation: Mechanism, diagnosis and clinical implication. Acta Derm Venereol (Stockh) Abstract 1994; 186:42.
57. Fisher DA. Allergic contact dermatitis to propylene glycol in calcipotriene ointment. Cutis 1997; 60:43-4. (Pubitemid 127470434)
58. Krayenbuhl BH, Elsner P. Allergic and irritant contact dermatitis to calcipotriol. Am J Contact Dermat 1999; 10:78-80. (Pubitemid 29269406)
59. Park YK, Lee JH, Chung WG. Allergic contact dermatitis from calcipotriol. Acta Derm Venereol 2002; 82:71-2.
60. Katayama I, Ohkawara A, Ohkido M, Harada S, Tamaki K, Nakagawa H, et al. High-concentration (20 μg/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids. Eur J Dermatol 2002; 12:553-7. (Pubitemid 35440792)
61. Queille-Roussel C, Duteil L, Parneix-Spake A, Arsonnaud S, Rizova E. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur J Dermatol 2001; 11:219-24. (Pubitemid 32472673)
62. Ortonne JP. Calcipotriol in combination with betametasone diproprionate. Nouv Dermatol 1994; 13:736-51.
63. Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg/g ointment and calcipotriol 50 microg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003; 148:326-33. (Pubitemid 36278976)
64. 3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr 1993; 152:389-92.
65. 3) for treating psoriasis in children. Arch Dermatol 1995; 131:961-2.
66. Travis LB, Silverberg NB. Psoriasis in infancy: therapy with calcipotriene ointment. Cutis 2001; 68:341-4. (Pubitemid 33756735)
67. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130:483-7. (Pubitemid 24204668)
68. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001; 2:159-65.
69. Koo J. Vitamin D and scalp psoriasis. Cutis 2002; 70:21-4.
70. Petrow W. Treatment of a nail psoriasis with calcipotriol. Akt Dermatol 1995; 21:396-400.
71. 3) for the treatment of psoriasis. Br J Dermatol 1996; 134:1070-8.
72. Kragballe K. Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica 1990; 181:211-4. (Pubitemid 20350477)
73. Kerscher M, Volkenandt M, Plewig G, Lehmann P. Combination phototherapy of psoriasis with calcipotriol and narrow band UVB. Lancet 1993; 342:923. (Pubitemid 23291600)
74. 3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: results of a controlled, right/left study. Br J Dermatol 2001; 144:628-9.
75. Tzaneva S, Honigsmann H, Tanew A, Seeber A. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002; 147:748-53. (Pubitemid 35286162)
76. Mascaro JM. Vitamin D and psoralen plus UVA radiation. Cutis 2002; 70:13-5.
77. Glaser R, Rowert J, Mrowietz U. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. Br J Dermatol 1998; 139:148-51. (Pubitemid 28338084)
78. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: a result of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31:68-74. (Pubitemid 24198166)
79. rd International Calcipotriol Symposium, Munich Germany, 23 March 1996.
80. van de Kerkhof P. Vitamin D and systemic therapy. Cutis 2002; 70:16-20.
81. de Jong EM, Mork NJ, Seijger MM, De La Brassine M, Lauharanta J, Jansen CT, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003; 148:318-25. (Pubitemid 36278975)
82. Monastirli A, Georgiou S, Pasmatzi E, Sakkis T, Badavanis G, Drainas D, et al. Calcipotriol plus shortcontact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol 2002; 15:246-51.
83. Campione E, Mazzotta A, Paternò EJ, Diluvio L, Prinz JC, Chimenti S. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriasi arthritis patients. Acta Derm Venereol 2009; 89:288-91.
84. 3 and its analogs for the treatment of psoriasis and other skin diseases. In: Vitamin D. Physiology, Molecular Biology and Clinical Applications (Editor: MF Holick). Humana Press Totowa, New Jersey 2010; 2:1043-60.
85. 3 analogues: a novel class of potent regulators of cell growth and immune response. Biochem Pharmacol 1991; 42:1569-75.
86. Neef G, Kirsch G, Schwarz K, Wiesinger H, Menrad A, Fähnrich M, et al. 20-methyl vitamin D analogues. In: Norman AW, Bouillon R, Thomasset M (Eds.). Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter Berlin 1994; 97-8.
87. Schönecker B, Reichenbächer M, Gliesing S, Prousa R, Wittmann S, Breiter S, et al. 2β-substituted calcitriols and other A-ring substituted analogues-synthesis and biological results. In: Norman AW, Bouillon R, Thomasset M, (Eds.). Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter Berlin 1994; 99-100.
88. Schuster I, Herzig G, Vorisek G. Steroidal hormones as modulators of vitamin D metabolism in human keratinocytes. In: Norman AW, Bouillon R, Thomasset M, (Eds.). Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter Berlin 1994; 184-5.
89. Zhao J, Marcelis S, Tan BK, Verstuaf A, Boillon R. Potentialisation of vitamin D (analogues) by cytochrom P-450 enzyme inhibitors is analog- and cell-type sepcific. In: Norman AW, Bouillon R, Thomasset M, (Eds.). Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter Berlin 1994; 97-8.
90. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W. Two nuclear signalling pathways for vitamin D. Nature 1993; 361:657-60. (Pubitemid 23062402)
91. Schräder M, Müller KM, Becker-Andre M, Carlberg C. Response element selectivity for heterodimerization of vitamin D receptors with retinoic acid and retinoid X receptors. J Mol Endocrinol 1994; 12:327-39. (Pubitemid 24199702)